A Prospective, Open-label, Dose Escalation (Part A) and Cohort Expansion (Part B) Phase 1 Study to Investigate the Safety, Tolerability, and Immunogenicity and to Determine Maximum Tolerated Dose and Recommended Phase 2 Dose of GC1118 (Recombinant Human Anti-EGFR Antibody) in Patients With Advanced Solid Cancers
Phase of Trial: Phase I
Latest Information Update: 05 Feb 2018
At a glance
- Drugs GC 1118A (Primary)
- Indications Colorectal cancer; Gastric cancer; Solid tumours
- Focus Adverse reactions
- Sponsors GC Pharma
- 02 Jan 2018 According to a GC Pharma media release, Green Cross Corporation rebrands itself to GC Pharma.
- 04 Jul 2016 Two part study changed to three part study; Part C (biweekly administration of GC 1118) added hence treatment revised.
- 04 Jul 2016 Planned number of patients changed from 66 to 72.